New Jersey-based Johnson & Johnson, a global health care company, plans to invest more than $1 billion to build a cell therapy manufacturing facility in Montgomery County.
The project will create more than 500 jobs over the next 12 years and retain 5,885 full-time jobs statewide.
The facility, which will be operated by Johnson & Johnson subsidiary Janssen Biotech, will be located in Lower Gwynedd Township and will directly support the production of medicines for cancer, immune-mediated, and neurological diseases.
“For 140 years, Johnson & Johnson has been a leading innovator in American healthcare, and we are honored to continue advancing that legacy in Pennsylvania,” Joaquin Duato, Johnson & Johnson chairman and CEO, said. “By uniting scientific excellence with state-of-the-art manufacturing and strategic investment, and by working collaboratively with our communities, we are delivering for patients and creating significant opportunities for workers and families.”
The Pennsylvania Department of Community & Economic Development (DCED) submitted a $41.5 million funding proposal to the company.
“This announcement also sends a clear message that Pennsylvania is competing — and winning — when it comes to attracting world-class life sciences companies, growing high-quality jobs, and driving long-term economic growth across the commonwealth,” DCED Secretary Rick Siger said.